Navigation Links
Schering-Plough Reports Top-Line Results of the IDEAL Study
Date:1/14/2008

completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths),
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
2. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Second Thoughts about Fluoride, Reports Scientific American
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
9. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 WuXi PharmaTech (Cayman) ... and technology platform company serving the pharmaceutical, ... small-molecule process development and manufacturing subsidiary Shanghai ... first approval from the Japan PMDA for ... a branded commercial drug in July. STA ...
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... 27, 2015 The global ... USD 3.96 billion by 2022, according to a new ... chronic venous disorders such as deep vein thrombosis, leg ... as the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) ... are also expected to boost market growth over the ...
Breaking Medicine Technology:WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... 4, 2011 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2011 third quarter financial results. ... over the internet on Tuesday, May 10, 2011 at 9:30 ... accessed by visiting the Company,s website at www.pro-dex.com . ...
... 4, 2011 Cardiogenesis Corporation (OTCQB: CGCP), a leading developer ... artery disease, today reported financial results for its first quarter ... quarter of 2011 was $3,053,000, a 6% decrease from prior ... net loss of $433,000, or $0.01 per basic and diluted ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast 2Cardiogenesis Reports First Quarter 2011 Results 2Cardiogenesis Reports First Quarter 2011 Results 3Cardiogenesis Reports First Quarter 2011 Results 4Cardiogenesis Reports First Quarter 2011 Results 5Cardiogenesis Reports First Quarter 2011 Results 6
(Date:8/27/2015)... , ... August 27, 2015 , ... According to an ... Conference on Abdominal Wall Hernia Surgery involved many conversations between hernia experts surrounding the ... there, the article notes that many different experts have different ideas about which is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, ... second year as sponsor of the “Music With A Mission” benefit concert. For the ... music education programs in the underfunded school districts of Mendon and neighboring town, Quincy, ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: